SynAct Pharma AB (OSTO:SYNACT) ROCE %: -58.66% (As of Mar. 2026)


OSTO:SYNACT SynAct Pharma AB OSTO:SYNACT
18 GF Score
Price kr15.06
! 1 Warning Sign
View Full Analysis

What is SynAct Pharma AB ROCE %?

SynAct Pharma AB OSTO:SYNACT -0.92% 18 ROCE % is -58.66% as of Mar. 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SynAct Pharma AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -58.66%.

SynAct Pharma AB  (OSTO:SYNACT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SynAct Pharma AB ROCE % Related Terms

SynAct Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for SynAct Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SynAct Pharma AB ROCE % Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -394.91 -141.83 -135.82 -40.61 -53.90

SynAct Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.04 -56.31 -63.52 -43.45 -58.66
OSTO:SYNACT
18GF Score
SynAct Pharma AB OSTO:SYNACT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SynAct Pharma AB ROCE % Calculation

SynAct Pharma AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-118.088/( ( (270.52 - 28.789) + (220.518 - 24.093) )/ 2 )
=-118.088/( (241.731+196.425)/ 2 )
=-118.088/219.078
=-53.90 %

SynAct Pharma AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-122.232/( ( (220.518 - 24.093) + (237.88 - 17.574) )/ 2 )
=-122.232/( ( 196.425 + 220.306 )/ 2 )
=-122.232/208.3655
=-58.66 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -58.66% mean?
SynAct Pharma AB (OSTO:SYNACT) has a ROCE % of -58.66% as of Mar. 2026.
Is SynAct Pharma AB's ROCE % too high?
SynAct Pharma AB's current ROCE % is -58.66%. Overall, SynAct Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's ROCE % compare to VRTX and REGN?
SynAct Pharma AB's ROCE % of -58.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. SynAct Pharma AB's current ROCE % is -58.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current ROCE % of -58.66%. The current ROCE % is -58.66%. SynAct Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current ROCE % is -58.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SynAct Pharma AB Business Description

Other Exchanges 8F8:Germany
Address Scheelevagen 2, Lund, SWE, 223 63
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
18GF Score

Get the complete analysis for OSTO:SYNACT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.06
Price